佛罗里达州的一项研究测试了用于治疗新生儿母亲产后抑郁症的迷幻双环细胞素。 A Florida study tests psychedelic psilocybin to treat postpartum depression in new mothers.

南佛罗里达大学的研究人员正在测试作为神奇蘑菇中活性化合物的psilocybin,作为临床试验中产后抑郁症的潜在治疗方法。 Researchers at the University of South Florida are testing psilocybin, the active compound in magic mushrooms, as a potential treatment for postpartum depression in a clinical trial. 该研究评估了其在减轻新母亲症状方面的安全和有效性,新母亲这一群体往往得不到目前的治疗。 The study evaluates its safety and effectiveness in alleviating symptoms for new mothers, a group often underserved by current therapies. 在非营利组织 Moms on Mushrooms 的支持下，这项研究是在严格的医疗监督和联邦指导下进行的，因为裸盖菇素仍然是附表 I 物质。 Supported by nonprofit Moms on Mushrooms, the research is conducted under strict medical supervision and federal guidelines, as psilocybin remains a Schedule I substance. 早期调查结果表明,一些参加者可能迅速得到缓解,但结果尚未确定。 Early findings suggest possible rapid relief for some participants, though results are still pending. 这次审判是国家日益努力探索精神健康状况的精神病治疗辅助疗法的一部分。 The trial is part of a growing national effort to explore psychedelic-assisted therapies for mental health conditions.